Nymox to Begin Trading on NASDAQ on November 25,1997.

ROCKVILLE, Md.--(BUSINESS WIRE)--Nov. 21, 1997--NYMOX(ME:NMX.) Nymox Corporation is pleased to announce that its shares will start trading on the NASDAQ National Market on November 25, 1997 under the symbol "NYMX".

Nymox Corporation is based in Rockville, MD and in Montreal, Canada.

Nymox currently trades on the Montreal Exchange (NMX). Nymox recently announced promising results in initial clinical trials of its new urinary test for Alzheimer's disease. The new test has been developed from Nymox's AD7C(TM) NTP based technologies, derived from an ongoing licensing collaboration between Nymox Corporation and the Massachusetts General Hospital. In addition to its Alzheimer testing technologies, the company has six treatment entities targeted for Phase One testing in the next 12 to 18 months, and two new diagnostics in development. Nymox currently has begun to launch its AD7C(TM) cerebrospinal fluid Reference Laboratory test in the U.S. and in Europe for use in Alzheimer's disease. The AD7C(TM) test was shown in multicenter clinical trials in 1996 to be as accurate as an autopsy in Alzheimer's disease. The full results from the AD7C(TM) spinal fluid studies will be made available through appropriate publication in a medical journal.

CONTACT: Nymox Pharmaceutical Corporation

Dr. Michael Munzar, 800/93NYMOX

info@nymox.com

http://www.nymox.com